If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Diabetes Prevention Program Utilizes Newly FDA-Approved Rezulin PHILADELPHIA, Jan. 31, 1997 -- The Food and Drug Administration (FDA) has approved a new drug called troglitazone, which will be sold under the brand name Rezulin by the end of March, that offers 1 million diabetics the hope of reducing -- and, for some, even stopping -- their insulin shots. Troglitazone is the first drug to attack the underlying trigger of Type II, or adult onset diabetes, the disease's most common form. It somehow resensitizes the body to insulin, a hormone that converts blood sugar into energy. Thomas Jefferson University Hospital has one of the largest diagnostic, treatment and research centers for diabetes in the country. Jefferson serves as one of 26 centers participating in the Diabetes Prevention Program (DPP), a nationwide National Institutes of Health (NIH) research study looking at ways people at risk for Type II diabetes can prevent or delay its onset. The DPP is divided into four investigational groups, one of which is designed to determine whether troglitazone can prevent or delay Type II diabetes in people at risk for it. Barry Goldstein, M.D., Ph.D., director of the division of endocrinology, diabetes and metabolic diseases and co-principal investigator of the DPP, is an expert on the diagnosis and management of diabetes and is widely knowledgeable on troglitazone and its potential.
|
